

Diagnose and Treat Hypothyroidism in 2021 Part 3: New Endocrinology

By Alan B. McDaniel, MD

Complete References

1. Hypothyroidism. *Taber's Medical Dictionary*. <https://www.tabers.com/tabersonline/view/Tabers-Dictionary/733926/all/hypothyroidism> Accessed 1.17.2020.
2. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. *Arch Intern Med*. 2000; 160:526-34. PMID: 10695693.
3. Hypothyroidism (Underactive Thyroid) NIH. NIDDKD. <https://www.niddk.nih.gov/health-information/endocrine-diseases/hypothyroidism> Accessed 1.22.2021
4. Rydzewska M, Jaromin M *et al*. Role of the T and B lymphocytes in pathogenesis of autoimmune thyroid diseases. *Thyroid Res*. 2018;11:2. PMID: 29449887.
5. Stahlman S. Thyroid Disorders, Active Component, U.S. Armed Forces, 2008–2017. *Health.mil*. 2018 <https://health.mil/News/Articles/2018/12/01/Thyroid-Disorders> Accessed 1.22.2021.
6. Khatari M. What does your thyroid do? *WebMD Medical Reference*. 2019. <https://www.webmd.com/a-to-z-guides/what-does-thyroid-do> Accessed 1.6.2021.
7. Mendoza A, Hollenberg AN. New Insights into Thyroid Hormone Action. *Pharmacol Ther*. 2017; 173: 135–145. PMID: 28174093.
8. Bakker O. Thyroid hormone receptors. Eds. Adashi EY, Bilezikian JP, Chrousos GP *et al*. *Encyclopedia of Endocrine Diseases*. Academic Press. 2004. ISBN 978-0-12-475570-3. <https://www.sciencedirect.com/topics/neuroscience/thyroid-hormone-receptor> Accessed 1.8.2021.
9. Symptoms underactive thyroid (hypothyroidism). NHS. 2018. <https://www.nhs.uk/conditions/underactive-thyroid-hypothyroidism/symptoms/> Accessed 1.22.2021.
10. Shahid MA, Ashraf MA, Sharma S. Physiology, Thyroid Hormone. *StatPearls [Internet]*. May 18, 2020. <https://www.ncbi.nlm.nih.gov/books/NBK500006/> Accessed 1.9.2021.
11. Molina PE. Endocrine physiology. *Lange physiology series*. The McGraw-Hill Companies, Inc. New York, NY. 2004. Page 83.



12. Bowen R. Control of thyroid hormone synthesis and secretion. *VIVO Pathophysiology*. <http://www.vivo.colostate.edu/hbooks/pathphys/endocrine/thyroid/control.html> Accessed 1.22.2021.
13. Zimmermann MB, Köhrle J. The impact of iron and selenium deficiencies on iodine and thyroid metabolism: biochemistry and relevance to public health. *Thyroid*. 2002; 12:867-78. PMID: 12487769.
14. Bowen R. Synthesis and secretion of thyroid hormones. *VIVO Pathophysiology*. <http://www.vivo.colostate.edu/hbooks/pathphys/endocrine/thyroid/synthesis.html> Accessed 1.22.2021
15. Refetoff S. Thyroid Hormone Serum Transport Proteins. *Endotext [Internet]*. 2015. PMID: 25905421. <https://www.ncbi.nlm.nih.gov/books/NBK285566/> Accessed 1.8.2021.
16. Davis PJ, Goglia F, Leonard JL. Nongenomic actions of thyroid hormone. *Nat Rev Endocrinol*. 2016; 12:111-21. PMID: 26668118.
17. Orozco A, Valverde-R C, Olvera A, García-G C. Iodothyronine deiodinases: a functional and evolutionary perspective. *J Endocrinol*. 2012; 215:207-19. PMID: 22872760.
18. Chiamolera MI, Wondisford FE. Thyrotropin-releasing hormone and the thyroid hormone feedback mechanism. *Endocrinol*. 2009; 150:1091-1096. PMID: 19179434.
19. Kopp P. Theodor Kocher (1841-1917) Nobel prize centenary 2009. *Arq Bras Endocrinol Metabol*. 2009; 53:1176-80. PMID: 20126876.
20. Peeters RP, van der Deure WM, Visser TJ. Genetic variation in thyroid hormone pathway genes; polymorphisms in the TSH receptor and the iodothyronine deiodinases. *Eur J Endocrinol*. 2006; 155:655-62. PMID: 17062880.
21. Fuentes AV, Pineda MD, Venkata KCN. Comprehension of Top 200 Prescribed Drugs in the US as a Resource for Pharmacy Teaching, Training and Practice. *Pharmacy (Basel)*. 2018; 6:43. PMID: 29757930.
22. "The Top 300 of 2021" ClinCalc DrugStats Database. <https://clincalc.com/DrugStats/Top300Drugs.aspx> Accessed 1.22.2021.
23. Top 10 Prescription Medications in the U.S. (August 2020). GoodRx. <https://www.goodrx.com/drug-guide> Accessed 1.21.2021.
24. Vanderpump MP. The epidemiology of thyroid disease. *Br Med Bull*. 2011; 99:39-51. PMID: 21893493.
25. Hollowell JG, Staehling NW *et al*. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab*. 2002; 87:489-99. PMID: 11836274.
26. Okayasu I, Hatakeyama S, Tanaka Y, Sakurai T, Hoshi K, Lewis PD. Is focal chronic autoimmune thyroiditis an age-related disease? Differences in incidence and severity between Japanese and British. *J Pathol*. 1991;163:257-64. PMID: 2013829.
27. Hypothyroidism (Underactive); FAQs. American Thyroid Association. <https://www.thyroid.org/hypothyroidism/> Accessed 1.23.2021.
28. Grüters A, Krude H. Update on the management of congenital hypothyroidism. *Horm Res*. 2007; 68 Suppl 5:107-11. PMID: 18174723.
29. Zimmermann MB. Iodine deficiency. *Endocr Rev*. 2009; 30:376-408. PMID: 19460960.
30. Zimmermann MB, Boelaert K. Iodine deficiency and thyroid disorders. *Lancet Diabetes Endocrinol*. 2015; 3:286-95. PMID: 25591468.

31. Visser TJ. The elemental importance of sufficient iodine intake: a trace is not enough. *Endocrinology*. 2006; 147:2095-7. PMID: 16617153.
32. Ezrin C, MacLachlan M, Walter EP, Volpe R. "Iodide-myxedema" in patients with chronic chest disease. *Can Med Assoc J*. 1961; 85:287-9. PMID: 13697753.
33. Leung AM, Braverman LE. Consequences of excess iodine. *Nat Rev Endocrinol*. 2014; 10:136-42. PMID: 24342882.
34. McKnight RF, Adida M *et al*. Lithium toxicity profile: a systematic review and meta-analysis. *Lancet*. 2012; 379(9817):721-8. PMID: 22265699.
35. Lazarus JH. Lithium and thyroid. *Best Pract Res Clin Endocrinol Metab*. 2009; 23:723-33. PMID: 19942149.
36. Vitamins & supplements: Lithium. *WebMD*. (<https://www.webmd.com/vitamins/ai/ingredientmono-1065/lithium> Accessed 1.16.2021.
37. Garber JR, Cobin RH, *et al*.; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. *Endocr Pract*. 2012; 18:988-1028. Erratum in: *Endocr Pract*. 2013; 19:175. PMID: 23246686.
38. Alan B. McDaniel, MD. abmcdaniel0621@gmail.com
39. Hyperthyroidism (overactive thyroid). *Mayo Foundation for Medical Education and Research*. <https://www.mayoclinic.org/diseases-conditions/hyperthyroidism/symptoms-causes/syc-20373659> Accessed 1.23.2021.
40. Saved from storymeister.tumblr.com. <https://www.pinterest.com/pin/307511480805061321/> Accessed 1.9.2021.
41. Techniques: Thyroid exam. Advanced Physical Diagnosis. University of Washington Department of Medicine. <https://depts.washington.edu/physdx/thyroid/tech.html> Accessed 1.23.2021.
42. McDaniel AB. Technique of Fine Needle Aspiration Biopsy for Autoimmune Thyroiditis. COSM Spring Scientific Meetings (AAOA), Palm Desert, CA; May 1995.
43. Yoshida H, Amino N *et al*. Association of serum antithyroid antibodies with lymphocytic infiltration of the thyroid gland: studies of seventy autopsied cases. *J Clin Endocrinol Metab*. 1978; 46:859-62. PMID: 263468.
44. Haugen BR, Alexander EK *et al*. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid*. 2016; 26:1-133. PMID: 26462967.
45. Santos Palacios S, Pascual-Corrales E, Galofre JC. Management of subclinical hyperthyroidism. *Int J Endocrinol Metab*. 2012; 10:490-6. PMID: 23843809.
46. Toft AD. Clinical practice. Subclinical hyperthyroidism. *N Engl J Med*. 2001;345:512-6. PMID: 11519506.
47. de Juan E Jr, Hurley DP, Sapira JD. Racial differences in normal values of proptosis. *Arch Intern Med*. 1980; 140:1230-1. PMID: 7406621.
48. Mackinnon SE, Fielding JC, Dellon AL, Fisher DM. The incidence and degree of scleral show in the normal population. *Plast Reconstr Surg*. 1987; 80:15-20. PMID: 3602156.

49. Demers LM, Spencer CA. Laboratory support for the diagnosis of thyroid disease. National Academy of Clinical Biochemistry. 2002. <https://www.aacc.org/science-and-research/practice-guidelines/thyroid-disease> Accessed 1.23.2021.
50. Garber JR, Cobin RH *et al.*; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism In Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. *Thyroid*. 2012; 22:1200-35. Erratum in: *Thyroid*. 2013 Feb;23(2):251. Erratum in: *Thyroid*. 2013 Jan;23(1):129. PMID: 22954017.
51. Ullah S, Helander A, Beck O. Identification and quantitation of phosphatidylethanol in oral fluid by liquid chromatography-tandem mass spectrometry. *Clin Chem Lab Med*. 2017; 55:1332-1339. PMID: 27988502.
52. Colon PJ, Greene DN. Biotin interference in clinical immunoassays. *J Appl Lab Med*. 2018; 2:941-51. <https://doi.org/10.1373/jalm.2017.024257> Accessed 1.23.2021.
53. Otten JJ, Pitz Hellwig J, Meyers LD Eds. Dietary reference intakes : the essential guide to nutrient requirements. Food and Nutrition Board, Institute of Medicine. National Academy Press, Washington, D.C. 2006; Pg. 323. https://www.nal.usda.gov/sites/default/files/fnic_uploads/DRIEssentialGuideNutReq.pdf Accessed 1.9.2021.
54. Kaplan IV, Levinson SS. When is a heterophile antibody not a heterophile antibody? When it is an antibody against a specific immunogen. *Clin Chem*. 1999; 45:616-8. PMID: 10222346.
55. Levinson SS. The nature of heterophilic antibodies and their role in immunoassay interference. *J Clin Immunoassay*. 1992; 15:108-15.
56. Pitt JJ. Principles and applications of liquid chromatography-mass spectrometry in clinical biochemistry. *Clin Biochem Rev*. 2009; 30:19-34. PMID: 19224008.
57. Hickner J, Thompson PJ *et al.* Primary care physicians' challenges in ordering clinical laboratory tests and interpreting results. *J Am Board Fam Med*. 2014; 27:268-74. PMID: 24610189.
58. Hoermann R, Midgley JE, Larisch R, Dietrich JW. Homeostatic Control of the Thyroid-Pituitary Axis: Perspectives for Diagnosis and Treatment. *Front Endocrinol (Lausanne)*. 2015; 6:177. PMID: 26635726.
59. Dayan CM, Saravanan P, Bayly G. Whose normal thyroid function is better--yours or mine? *Lancet*. 2002; 360:353. PMID: 12241772.
60. Kooistra HS, Diaz-Espineira M *et al.* Secretion pattern of thyroid-stimulating hormone in dogs during euthyroidism and hypothyroidism. *Domest Anim Endocrinol*. 2000; 18:19-29. PMID: 10701761.
61. Bruhn TO, McFarlane MB, Deckey JE, Jackson IM. Analysis of pulsatile secretion of thyrotropin and growth hormone in the hypothyroid rat. *Endocrinology*. 1992; 131:2615-21. PMID: 1446603.
62. Roelfsema F, Veldhuis JD. Thyrotropin secretion patterns in health and disease. *Endocr Rev*. 2013; 34:619-57. PMID: 23575764.
63. Dietrich JW, Midgley JEM, Hoermann R. Editorial: "Homeostasis and Allostasis of Thyroid Function". *Front Endocrinol (Lausanne)*. 2018; 9:287. PMID: 29922229.

64. Spencer CA, Hollowell JG, Kazarosyan M, Braverman LE. National Health and Nutrition Examination Survey III thyroid-stimulating hormone (TSH)-thyroperoxidase antibody relationships demonstrate that TSH upper reference limits may be skewed by occult thyroid dysfunction. *J Clin Endocrinol Metab.* 2007; 92:4236-40. PMID: 17684054.
65. Chopra IJ. An assessment of daily production and significance of thyroidal secretion of 3, 3', 5'-triiodothyronine (reverse T3) in man. *J Clin Invest.* 1976; 58:32-40. PMID: 932209.
66. Tegler L, Gillquist J, Lindvall R, Almqvist S. Secretion rates of thyroxine, triiodothyronine, and reverse triiodothyronine in man during surgery. *Acta Endocrinol (Copenh).* 1982; 101:193-8. PMID: 6215812.
67. Bianco AC, Salvatore D *et al.* Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. *Endocr Rev.* 2002; 23:38-89. PMID: 11844744.
68. Kratzsch J, Fiedler GM *et al.* New reference intervals for thyrotropin and thyroid hormones based on National Academy of Clinical Biochemistry criteria and regular ultrasonography of the thyroid. *Clin Chem.* 2005; 51:1480-6. PMID: 15961550.
69. Hulbert AJ. Thyroid hormones and their effects: a new perspective. *Biol Rev Camb Philos Soc.* 2000; 75:519-631. PMID: 11117200.
70. Hennemann G, Docter R *et al.* Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. *Endocr Rev.* 2001; 22:451-76. PMID: 11493579.
71. Peeters RP, Visser TJ. Metabolism of thyroid hormone. Endotext [Internet]. NCBI Bookshelf 2017. PMID: 25905401. <https://www.ncbi.nlm.nih.gov/books/NBK285545/> Accessed 1.10.2021.
72. Goode AW, Herring AN *et al.* The effect of surgery with carbohydrate infusion on circulating triiodothyronine and reverse triiodothyronine. *Ann R Coll Surg Engl.* 1981; 63:168-72. PMID: 7247276.
73. Wartofsky L, Burman KD. Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome". *Endocr Rev.* 1982; 3:164-217. PMID: 6806085.
74. Katzeff HL, Powell SR, Ojamaa K. Alterations in cardiac contractility and gene expression during low-T3 syndrome: prevention with T3. *Am J Physiol.* 1997; 273:E951-6. PMID: 9374681.
75. Kuiper GG, Kester MH, Peeters RP, Visser TJ. Biochemical mechanisms of thyroid hormone deiodination. *Thyroid.* 2005; 15:787-98. PMID: 16131322.
76. Maia AL, Kim BW *et al.* Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. *J Clin Invest.* 2005; 115:2524-33. PMID: 16127464.
77. Peeters RP, Wouters PJ *et al.* Serum 3,3',5'-triiodothyronine (rT3) and 3,5,3'-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. *J Clin Endocrinol Metab.* 2005; 90:4559-65. PMID: 15886232.
78. Smit JW, Stokkel MP *et al.* Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones. *J Clin Endocrinol Metab.* 2007; 92:2496-9. PMID: 17440015.
79. Peeters RP, van der Geyten S *et al.* Tissue thyroid hormone levels in critical illness. *J Clin Endocrinol Metab.* 2005; 90:6498-507. PMID: 16174716.

80. Hoermann R, Midgley JE, Larisch R, Dietrich JW. Relational Stability of Thyroid Hormones in Euthyroid Subjects and Patients with Autoimmune Thyroid Disease. *Eur Thyroid J*. 2016; 5:171-179. PMID: 27843807.
81. Chistiakov DA. Immunogenetics of Hashimoto's thyroiditis. *J Autoimmune Dis*. 2005; 2:1. PMID: 15762980.
82. Ehlers M, Thiel A *et al*. Evidence of a combined cytotoxic thyroglobulin and thyroperoxidase epitope-specific cellular immunity in Hashimoto's thyroiditis. *J Clin Endocrinol Metab*. 2012; 97:1347-54. PMID: 22259066.
83. McLachlan SM, Rapoport B. Autoimmune response to the thyroid in humans: thyroid peroxidase--the common autoantigenic denominator. *Int Rev Immunol*. 2000; 19:587-618. PMID: 11129117.
84. Barić A, Brčić L *et al*. Thyroglobulin Antibodies are Associated with Symptom Burden in Patients with Hashimoto's Thyroiditis: A Cross-Sectional Study. *Immunol Invest*. 2019; 48:198-209. PMID: 30332318.
85. Franco JS, Jenny Amaya-Amaya J, Anaya JM. Thyroid disease and autoimmune diseases. *Autoimmunity: From Bench to Bedside [Internet]*. 2013. Bookshelf ID: NBK459466. <https://www.ncbi.nlm.nih.gov/books/NBK459466/> Accessed 1.11.2021.
86. Zöphel K, Roggenbuck D, Schott M. Clinical review about TRAb assay's history. *Autoimmun Rev*. 2010; 9:695-700. PMID: 20594972.
87. Mincer DL, Jialal I. Hashimoto Thyroiditis. 2020 Aug 10. In: *StatPearls [Internet]*. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. PMID: 29083758.
88. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. *Endocr Rev*. 2008; 29:76-131. PMID: 17991805.
89. Markou K, Georgopoulos V *et al*. Iodine-induced hypothyroidism. *Thyroid*. 2001; 11:501-10. PMID: 11396709.
90. Iodine deficiency. *Nutrition Landscape Information System (NLIS)*. World Health Organization. 2013 <https://www.who.int/data/nutrition/nlis/info/iodine-deficiency> Accessed 1.24.2021.
91. Zava T. Evaluation of the Iodine Loading Test: Urine Iodine Excretion Kinetics after Consumption of 50 mg Iodine/Iodide. *Townsend Letter*. 2013 Jan. <https://www.townsendletter.com/Jan2013/iodine0113.html> Accessed 1.26.2020.
92. Gaby A. Letter: Alan Gaby replies. *Townsend Letter*. 2011 Feb/ Mar. <https://www.thefreelibrary.com/Alan+Gaby+replies.-a0250827396> Accessed 1.11.2021.
93. Perrild H, Hegedüs L *et al*. Thyroid function and ultrasonically determined thyroid size in patients receiving long-term lithium treatment. *Am J Psychiatry*. 1990; 147:1518-21. PMID: 2221166.
94. Wilson, ED. *Wilson's Syndrome. The miracle of feeling well*. Cornerstone Publishing Co. Orlando, FL. 1991. ISBN 0-9629875-0-6.
95. Barnes, BO, Galton L. *Hypothyroidism: the unsuspected illness*. Harper & Row. New York, NY. 1976. ISBN 0-690-01029-X.
96. Leung AM, Braverman LE. Iodine-induced thyroid dysfunction. *Curr Opin Endocrinol Diabetes Obes*. 2012; 19:414-9. PMID: 22820214.

97. Rose HR, Zulfiqar H. Jod Basedow Syndrome. 2020 Oct 7. In: *StatPearls [Internet]*. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 31334997. <https://www.ncbi.nlm.nih.gov/books/NBK544277/> Accessed 1.24.2021.
98. Zimmermann MB, Ito Y *et al.* High thyroid volume in children with excess dietary iodine intakes. *Am J Clin Nutr.* 2005; 81:840-4. Erratum in: *Am J Clin Nutr.* 2005; 82:203. PMID: 15817861.
99. Inoue K, Leung AM *et al.* Urinary Iodine Concentration and Mortality Among U.S. Adults. *Thyroid.* 2018; 28:913-920. PMID: 29882490.
100. Jonklaas J, Bianco AC *et al.*; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. *Thyroid.* 2014; 24:1670-751. PMID: 25266247.
101. Brent GA, Larsen PR, Davies TF. Hypothyroidism and thyroiditis. In: *Williams textbook of endocrinology, Ed 11.* Saunders Elsevier. Philadelphia PA. 2008. ISBN: 9781416029113. Page 397.
102. Bekkering GE, Agoritsas T *et al.* Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. *BMJ.* 2019; 365:l2006. PMID: 31088853.
103. McDaniel, AB. An approach to managing fibromyalgia and chronic pain. *Townsend Letter.* 2020 Nov; (448):31-6.
104. Johnson EO, Calogero AE *et al.* Effects of short- and long-duration hypothyroidism on hypothalamic-pituitary-adrenal axis function in rats: in vitro and in situ studies. *Endocrine.* 2012; 42:684-93. PMID: 22695985.
105. Murray JS, Jayarajasingh R, Perros P. Lesson of the week: Deterioration of symptoms after start of thyroid hormone replacement. *BMJ.* 2001; 323:332-3. PMID: 11498494.
106. Conde SJ, Luvizotto Rde A, de Sábio MT, Nogueira CR. Thyroid hormone status interferes with estrogen target gene expression in breast cancer samples in menopausal women. *ISRN Endocrinol.* 2014; 2014:317398. PMID: 24701358.
107. Meng R, Tang HY *et al.* Crosstalk between integrin $\alpha\beta3$ and estrogen receptor- α is involved in thyroid hormone-induced proliferation in human lung carcinoma cells. *PLoS One.* 2011; 6:e27547. PMID: 22132110.
108. Vasudevan N, Koibuchi N, Chin WW, Pfaff DW. Differential crosstalk between estrogen receptor (ER)alpha and ERbeta and the thyroid hormone receptor isoforms results in flexible regulation of the consensus ERE. *Brain Res Mol Brain Res.* 2001; 95:9-17. PMID: 11687272.
109. Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. *Nat Clin Pract Endocrinol Metab.* 2005;1:32-40. PMID: 16929364.
110. Yousef A, Justin Clark J, Doi SAR. Thyroxine suppression therapy for benign, non-functioning solitary thyroid nodules: A quality-effects meta-analysis. *Clin Med Res.* 2010; 8:150-8. PMID: 20739581.
111. Sawin CT, Geller A *et al.* The aging thyroid. The use of thyroid hormone in older persons. *JAMA.* 1989; 261:2653-5. PMID: 2709545.

112. Parle JV, Franklyn JA *et al.* Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment. *Br J Gen Pract.* 1993;43:107-9. PMID: 8323787.
113. Roos A, Linn-Rasker SP *et al.* The starting dose of levothyroxine in primary hypothyroidism treatment: a prospective, randomized, double-blind trial. *Arch Intern Med.* 2005; 165:1714-20. Erratum in: *Arch Intern Med.* 2005;165:2227. PMID: 16087818.
114. Santini F, Pinchera A *et al.* Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. *J Clin Endocrinol Metab.* 2005; 90:124-7. PMID: 15483074.
115. Jansen SW, Akintola AA *et al.* Human longevity is characterised by high thyroid stimulating hormone secretion without altered energy metabolism. *Sci Rep.* 2015; 5:11525. PMID: 26089239.
116. Scanlon MF, Weetman AP *et al.* Dopaminergic modulation of circadian thyrotropin rhythms and thyroid hormone levels in euthyroid subjects. *J Clin Endocrinol Metab.* 1980; 51:1251-6. PMID: 7440694.
117. Sturgess I, Thomas SH *et al.* Diurnal variation in TSH and free thyroid hormones in patients on thyroxine replacement. *Acta Endocrinol (Copenh).* 1989; 121:674-6. PMID: 2588938.
118. Gidal BE, Clark AM, Anders B, Gilliam F. The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate. *Epilepsy Res.* 2017 Jan; 129:26-32. doi: 10.1016/j.epilepsyres.2016.10.020. PMID: 27883934. Figure 3. <https://www.sciencedirect.com/science/article/pii/S0920121116302613?via%3Dihub> Accessed 1.14.2021.
119. Adinoff B. Divided doses for methadone maintenance. *Am J Psychiatry.* 2008 Mar;165(3):303-5. doi: 10.1176/appi.ajp.2007.07121944. PMID: 18316426. Figure 1. <https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.2007.07121944> Accessed 1.14.2021.
120. Osler W. *The principles and practice of medicine, 4th Ed.* Young J. Pentland. Edinburgh & London 1901; page 843.
121. Bolk N, Visser TJ *et al.* Effects of evening vs. morning levothyroxine intake. *Arch Intern Med.* 2010; 170:1996-2003. PMID: 21149757.
122. McMillan M, Rotenberg KS *et al.* Comorbidities, Concomitant Medications, and Diet as Factors Affecting Levothyroxine Therapy: Results of the CONTROL Surveillance Project. *Drugs R D.* 2016; 16:53-68. PMID: 26689565.
123. Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. *JAMA.* 2000; 283:2822-5. PMID: 10838651.
124. Chorazy PA, Himelhoch S *et al.* Persistent hypothyroidism in an infant receiving a soy formula: case report and review of the literature. *Pediatrics.* 1995; 96:148-50. PMID: 7596704.
125. Bell DS, Ovalle F. Use of soy protein supplement and resultant need for increased dose of levothyroxine. *Endocr Pract.* 2001; 7:193-4. PMID: 11421567.
126. Hueston WJ. Treatment of hypothyroidism. *Am Fam Physician.* 2001; 64:1717-24. Erratum in: *Am Fam Physician* 2002; 65:2438. PMID: 11759078.

127. Kansagra SM, McCudden CR, Willis MS. The Challenges and Complexities of Thyroid Hormone Replacement. *Lab Med.* 2010; 41:338-48. <https://doi.org/10.1309/LMB39TH2FZGNDGIM>. Accessed 1.25.2021.
128. Hertoghe T. *The hormone handbook*. International Medical Books. Windhof, Luxembourg. 2006. ISBN: 978-2-9599713-0-3.
129. Thyroid Q&A: TSH. American Thyroid Association. <https://www.thyroid.org/patient-thyroid-information/what-are-thyroid-problems/q-and-a-tsh-thyroid-stimulating-hormone/> Accessed 1.25.2020.
130. Haug E. Behandling av hypotyreose [Treatment of hypothyroidism]. *Tidsskr Nor Laegeforen.* 2002; 122:935-7. Norwegian. PMID: 12082840.
131. Vanderpump MP, Tunbridge WM *et al.* The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. *Clin Endocrinol (Oxf).* 1995; 43:55-68. PMID: 7641412.
132. Ross DS, Daniels GH, Gouveia D. The use and limitations of a chemiluminescent thyrotropin assay as a single thyroid function test in an out-patient endocrine clinic. *J Clin Endocrinol Metab.* 1990; 71:764-9. PMID: 2394778.
133. Hennessey JV, Espallat R. Current evidence for the treatment of hypothyroidism with levothyroxine/levotriiodothyronine combination therapy versus levothyroxine monotherapy. *Int J Clin Pract.* 2018; 72:e13062. PMID: 29381251.
134. Peterson SJ, Cappola AR *et al.* An Online Survey of Hypothyroid Patients Demonstrates Prominent Dissatisfaction. *Thyroid.* 2018; 28:707-721. PMID: 29620972.
135. Carlé A, Faber J *et al.* Hypothyroid Patients Encoding Combined MCT10 and DIO2 Gene Polymorphisms May Prefer L-T3 + L-T4 Combination Treatment - Data Using a Blind, Randomized, Clinical Study. *Eur Thyroid J.* 2017; 6:143-151. PMID: 28785541.
136. Panicker V, Saravanan P *et al.* Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. *J Clin Endocrinol Metab.* 2009; 94:1623-9. PMID: 19190113.
137. Verloop H, Dekkers OM *et al.* Genetics in endocrinology: genetic variation in deiodinases: a systematic review of potential clinical effects in humans. *Eur J Endocrinol.* 2014 Sep;171(3):R123-35. PMID: 24878678.
138. Bowthorpe, JA. *Stop the thyroid madness*. Fredericksburg, TX. Laughing Grape Publishing. 2008. ISBN: 978-0-615-47712-1.
139. Kharrazian D. *Why do I still have thyroid symptoms? When my lab tests are normal*. Morgan James Publishing LLC. Garden City, NY. 2011.
140. Celi FS, Zemskova M *et al.* The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients. *Clin Endocrinol (Oxf).* 2010; 72:709-15. PMID: 20447070.
141. Gereben B, Goncalves C *et al.* Selective proteolysis of human type 2 deiodinase: a novel ubiquitin-proteasomal mediated mechanism for regulation of hormone activation. *Mol Endocrinol.* 2000; 14:1697-708. PMID: 11075806.
142. Nicod P, Burger A, Staeheli V, Vallotton MB. Radioimmunoassay for 3,3',5'-triiodo-L-thyronine in unextracted serum: method and clinical results. *J Clin Endocrinol Metab.* 1976; 42:823-9. PMID: 1270576.

143. Dorfman SG, Young RL. T4-thyrotoxicosis. *Arch Intern Med.* 1978; 138:1016-7. PMID: 580554.
144. Larisch R, Midgley JEM, Dietrich JW, Hoermann R. Symptomatic Relief is Related to Serum Free Triiodothyronine Concentrations during Follow-up in Levothyroxine-Treated Patients with Differentiated Thyroid Cancer. *Exp Clin Endocrinol Diabetes.* 2018; 126:546-552. PMID: 29396968.
145. Jonklaas J, Davidson B, Bhagat S, Soldin SJ. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. *JAMA.* 2008; 299:769-77. PMID: 18285588.
146. Verburg FA, Smit JW *et al.* Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy. *Clin Endocrinol (Oxf).* 2012; 76:577-81. PMID: 22017394.
147. Orlická E, Vondra K *et al.* TRH test in patients with diabetes mellitus type 1 and/or autoimmune thyroiditis. Changes in the pituitary-thyroid axis, reverse T3, prolactin and growth hormone levels. *Physiol Res.* 2008; 57 Suppl 1:S109-17. PMID: 18271686.
148. Volta C, Ghizzoni L, Davoli A, D'Amato L, Panza C, Bernasconi S. Thyroid function tests in children with congenital hypothyroidism on L-thyroxine treatment. *Horm Res.* 1989; 32:109-12. PMID: 2625320.
149. Morita T, Tamai H *et al.* Changes in serum thyroid hormone, thyrotropin and thyroglobulin concentrations during thyroxine therapy in patients with solitary thyroid nodules. *J Clin Endocrinol Metab.* 1989; 69:227-30. PMID: 2753971.
150. Sommardahl CS, Frank N *et al.* Effects of oral administration of levothyroxine sodium on serum concentrations of thyroid gland hormones and responses to injections of thyrotropin-releasing hormone in healthy adult mares. *Am J Vet Res.* 2005; 66:1025-31. PMID: 16008227.
151. Banovac K, Zakarija M, Rabinovitch A. A study of hepatic metabolism of thyroxine in BB/W rats treated with L-thyroxine. *Horm Metab Res.* 1989; 21:69-72. PMID: 2722130.
152. Surks MI, Schadlow AR, Stock JM, Oppenheimer JH. Determination of iodothyronine absorption and conversion of L-thyroxine (T₄) to L-triiodothyronine (T₃) using turnover rate techniques. *J Clin Invest.* 1973; 52:805-11 PMID: 4693647.
153. St Germain DL, Galton VA, Hernandez A. Minireview: Defining the roles of the iodothyronine deiodinases: current concepts and challenges. *Endocrinology.* 2009; 150:1097-107 PMID: 19179439.
154. Nauman A, Kamiński T, Herbaczyńska-Cedro K. In vivo and in vitro effects of adrenaline on conversion of thyroxine to triiodothyronine and to reverse-triiodothyronine in dog liver and heart. *Eur J Clin Invest.* 1980; 10:189-92. PMID: 6783414.
155. Chopra IJ, Williams DE, Orgiazzi J, Solomon DH. Opposite effects of dexamethasone on serum concentrations of 3,3',5'-triiodothyronine (reverse T3) and 3,3',5'-triiodothyronine (T3). *J Clin Endocrinol Metab.* 1975; 41:911-20. PMID: 1242390.
156. Burr WA, Ramsden DB *et al.* Effect of a single dose of dexamethasone on serum concentrations of thyroid hormones. *Lancet.* 1976; 2(7976):58-61. PMID: 59147.

157. Verhoeven RP, Visser TJ *et al.* Plasma thyroxine, 3,3',5-triiodothyronine and 3,3',5'-triiodothyronine during beta-adrenergic blockade in hyperthyroidism. *J Clin Endocrinol Metab.* 1977; 44:1002-5. PMID: 576870.
158. Tagami T, Yambe Y *et al.*; BBGD Study Group. Short-term effects of β -adrenergic antagonists and methimazole in new-onset thyrotoxicosis caused by Graves' disease. *Intern Med.* 2012; 51:2285-90. PMID: 22975536.
159. Kennedy RL, Griffiths H, Gray TA. Amiodarone and the thyroid. *Clin Chem.* 1989; 35:1882-7. PMID: 2673586.
160. Smith SM, Finley J, Johnson LK, Lukaski HC. Indices of in vivo and in vitro thyroid hormone metabolism in iron-deficient rats. *Nutrition Research.* 1994; 14:729-39. [https://doi.org/10.1016/S0271-5317\(05\)80208-8](https://doi.org/10.1016/S0271-5317(05)80208-8). Accessed 1.25.2021.
161. Economidou F, Douka E *et al.* Thyroid function during critical illness. *Hormones (Athens).* 2011; 10:117-24. PMID: 21724536.
162. Gereben B, Zavacki AM *et al.* Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. *Endocr Rev.* 2008; 29:898-938. PMID: 18815314.
163. Boelen A, Platvoet-ter Schiphorst MC, Bakker O, Wiersinga WM. The role of cytokines in the lipopolysaccharide-induced sick euthyroid syndrome in mice. *J Endocrinol.* 1995; 146:475-83. PMID: 7595143.
164. van der Poll T, Endert E *et al.* Neutralization of TNF does not influence endotoxin-induced changes in thyroid hormone metabolism in humans. *Am J Physiol.* 1999; 276:R357-62. PMID: 9950912.
165. Somppi TL. Non-Thyroidal Illness Syndrome in Patients Exposed to Indoor Air Dampness Microbiota Treated Successfully with Triiodothyronine. *Front Immunol.* 2017; 8:919. PMID: 28824644.
166. Ruhla S, Arafat AM *et al.* T3/rT3-ratio is associated with insulin resistance independent of TSH. *Horm Metab Res.* 2011; 43:130-4. PMID: 21104580.
167. Romitti M, Wajner SM *et al.* Increased type 3 deiodinase expression in papillary thyroid carcinoma. *Thyroid.* 2012; 22:897-904. PMID: 22823995.
168. Vigone MC, Cortinovis F *et al.* Difficult treatment of consumptive hypothyroidism in a child with massive parotid hemangioma. *J Pediatr Endocrinol Metab.* 2012; 25:153-5. PMID: 22570966.
169. Douyon L, Schteingart DE. Effect of obesity and starvation on thyroid hormone, growth hormone, and cortisol secretion. *Endocrinol Metab Clin North Am.* 2002; 31:173-89. PMID: 12055988.
170. Langouche L, Jacobs A, Van den Berghe G. Nonthyroidal Illness Syndrome Across the Ages. *J Endocr Soc.* 2019; 3:2313-2325. PMID: 31745528.
171. Huang SA, Bianco AC. Reawakened interest in type III iodothyronine deiodinase in critical illness and injury. *Nat Clin Pract Endocrinol Metab.* 2008; 4:148-55. PMID: 18212764.
172. Sabatino L, Cerillo AG *et al.* Is the low tri-iodothyronine state a crucial factor in determining the outcome of coronary artery bypass patients? Evidence from a clinical pilot study. *J Endocrinol.* 2002; 175:577-86.. PMID: 12475369.

173. Boelen A, Kwakkel J, Fliers E. Beyond low plasma T3: local thyroid hormone metabolism during inflammation and infection. *Endocr Rev.* 2011; 32:670-93. PMID: 21791567.
174. Haas NA, Camphausen CK, Kececioğlu D. Clinical review: thyroid hormone replacement in children after cardiac surgery--is it worth a try? *Crit Care (London, England).* 2006;10:213. PMID: 16719939.
175. Michalaki M, Vagenakis AG *et al.* Dissociation of the early decline in serum T(3) concentration and serum IL-6 rise and TNFalpha in nonthyroidal illness syndrome induced by abdominal surgery. *J Clin Endocrinol Metab.* 2001; 86:4198-205. PMID: 11549650.
176. Arunabh, Sarda AK, Karmarkar MG. Changes in thyroid hormones in surgical trauma. *J Postgrad Med.* 1992; 38:117-8. PMID: 1303410.
177. Langer P, Balázová E *et al.* Acute development of low T3 syndrome and changes in pituitary-adrenocortical function after elective cholecystectomy in women: some differences between young and elderly patients. *Scand J Clin Lab Invest.* 1992; 52:215-20. PMID: 1329184.
178. Kelly GS. Peripheral metabolism of thyroid hormones: a review. *Altern Med Rev.* 2000; 5:306-33. PMID: 10956378.
179. Friberg L, Drvota V *et al.* Association between increased levels of reverse triiodothyronine and mortality after acute myocardial infarction. *Am J Med.* 2001; 111:699-703. PMID: 11747849.
180. Jakowczuk M, Zalas D, Owecki M. Permanent atrial fibrillation in heart failure patients as another condition with increased reverse triiodothyronine concentration. *Neuro Endocrinol Lett.* 2016; 37:337-342. PMID: 27857052.
181. Köhrle J. The Colorful Diversity of Thyroid Hormone Metabolites. *Eur Thyroid J.* 2019; 8:115-129. PMID: 31259154.
182. Piehl S, Hoefig CS, Scanlan TS, Köhrle J. Thyronamines--past, present, and future. *Endocr Rev.* 2011; 32:64-80. PMID: 20880963.
183. Pitman CS, Barker SB. Inhibition of thyroxine action by 3,3',5'-triiodothyronine. *Endocrinology.* 1959; 64:466-8. PMID: 13630270.
184. Pittman JA, Tingley JO, Nickerson JF, Hill SR Jr. Antimetabolic activity of 3,3',5'-triiodo-DL-thyronine in man. *Metabolism.* 1960; 9:293-5. PMID: 14433319.
185. Barker SB, Pittman CS, Pittman JA Jr, Hill SR Jr. Thyroxine antagonism by partially iodinated thyronines and analogues. *Ann N Y Acad Sci.* 1960; 86:545-62. PMID: 13796818.
186. Latham KR, Ring JC, Baxter JD. Solubilized nuclear "receptors" for thyroid hormones. Physical characteristics and binding properties, evidence for multiple forms. *J Biol Chem.* 1976; 251(23):7388-97. PMID: 12162.
187. Bobek S, Sechman A, Niezgoda J, Jacek T. Reverse 3,3',5'-triiodothyronine suppresses increase in free fatty acids in chickens elicited by dexamethasone or adrenaline. *J Vet Med A Physiol Pathol Clin Med.* 2002; 49:121-4. PMID: 12019951.
188. Tien ES, Matsui K, Moore R, Negishi M. The nuclear receptor constitutively active/androstane receptor regulates type 1 deiodinase and thyroid hormone activity in the regenerating mouse liver. *J Pharmacol Exp Ther.* 2007; 320:307-13. PMID: 17050775.

189. Smith HC, Robinson SE, Eastman CJ. Binding of reverse T3 to hepatic nuclear protein. *Aust J Exp Biol Med Sci.* 1980; 58:207-12. PMID: 7436879.
190. Smith HC, Robinson SE, Eastman CJ. Binding of endogenous iodothyronines to isolated liver cell nuclei. *Endocrinology.* 1980; 106:1133-6. PMID: 6244141.
191. Mitchell AM, Manley SW, Rowan KA, Mortimer RH. Uptake of reverse T3 in the human choriocarcinoma cell line, JAr. *Placenta.* 1999; 20:65-70. PMID: 9950146.
192. Huang CJ, Geller HM, Green WL, Craelius W. Acute effects of thyroid hormone analogs on sodium currents in neonatal rat myocytes. *J Mol Cell Cardiol.* 1999; 31:881-93. PMID: 10329215.
193. Okamoto R, Leibfritz D. Adverse effects of reverse triiodothyronine on cellular metabolism as assessed by ¹H and ³¹P NMR spectroscopy. *Res Exp Med (Berl).* 1997; 197:211-7. PMID: 9440139.
194. St Germain DL. Metabolic effect of 3,3',5'-triiodothyronine in cultured growth hormone-producing rat pituitary tumor cells. Evidence for a unique mechanism of thyroid hormone action. *J Clin Invest.* 1985; 76:890-3. PMID: 4031075.
195. Kaiser CA, Goumaz MO, Burger AG. In vivo inhibition of the 5'-deiodinase type II in brain cortex and pituitary by reverse triiodothyronine. *Endocrinology.* 1986; 119:762-70. PMID: 3732144.
196. Obregon MJ, Larsen PR, Silva JE. The role of 3,3',5'-triiodothyronine in the regulation of type II iodothyronine 5'-deiodinase in the rat cerebral cortex. *Endocrinology.* 1986; 119:2186-92. PMID: 3769868.
197. Branco M, Ribeiro M, Negrão N, Bianco AC. 3,5,3'-Triiodothyronine actively stimulates UCP in brown fat under minimal sympathetic activity. *Am J Physiol.* 1999; 276:E179-87. PMID: 9886965.
198. Cettour-Rose P, Visser TJ, Burger AG, Rohner-Jeanrenaud F. Inhibition of pituitary type 2 deiodinase by reverse triiodothyronine does not alter thyroxine-induced inhibition of thyrotropin secretion in hypothyroid rats. *Eur J Endocrinol.* 2005; 153:429-34. PMID: 16131606.
199. St Germain DL. Dual mechanisms of regulation of type I iodothyronine 5'-deiodinase in the rat kidney, liver, and thyroid gland. Implications for the treatment of hyperthyroidism with radiographic contrast agents. *J Clin Invest.* 1988; 81:1476-84. PMID: 2835397.
200. St Germain DL, Croteau W. Ligand-induced inactivation of type I iodothyronine 5'-deiodinase: protection by propylthiouracil in vivo and reversibility in vitro. *Endocrinology.* 1989; 125:2735-44. PMID: 2792006.
201. Zhu B, Shrivastava A *et al.* Catalysis leads to posttranslational inactivation of the type 1 deiodinase and alters its conformation. *J Endocrinol.* 2012; 214:87-94. PMID: 22544951.
202. Shigematsu H, Smith RA, Shatney CH. Detrimental effect of reverse triiodothyronine in hemorrhagic shock. *Crit Care Med.* 1987; 15:933-8. PMID: 3652709.
203. LoPresti JS, Fried JC, Spencer CA, Nicoloff JT. Unique alterations of thyroid hormone indices in the acquired immunodeficiency syndrome (AIDS). *Ann Intern Med.* 1989; 110:970-5. PMID: 2567143.

204. Lambert M, Zech F *et al.* Elevation of serum thyroxine-binding globulin (but not of cortisol-binding globulin and sex hormone-binding globulin) associated with the progression of human immunodeficiency virus infection. *Am J Med.* 1990; 89:748-51. PMID: 2147539.
205. Crenn P, Rakotoanbinina B *et al.* Hyperphagia contributes to the normal body composition and protein-energy balance in HIV-infected asymptomatic men. *J Nutr.* 2004; 134:2301-6. PMID: 15333720.
206. Roef G, Lapauw B *et al.* Body composition and metabolic parameters are associated with variation in thyroid hormone levels among euthyroid young men. *Eur J Endocrinol.* 2012; 167:719-26. PMID: 22956557.
207. Moura Neto A, Zantut-Wittmann DE. Abnormalities of Thyroid Hormone Metabolism during Systemic Illness: The Low T3 Syndrome in Different Clinical Settings. *Int J Endocrinol.* 2016; 2016:2157583. PMID: 27803712.
208. Fraczek-Jucha M, Zbierska-Rubinkiewicz K *et al.* Low triiodothyronine syndrome and selenium deficiency - undervalued players in advanced heart failure? A single center pilot study. *BMC Cardiovasc Disord.* 2019; 19:105. Erratum in: *BMC Cardiovasc Disord.* 2019;19:133. PMID: 31064347.
209. Gomes-Lima C, Wartofsky L, Burman K. Can Reverse T3 Assay Be Employed to Guide T4 vs. T4/T3 Therapy in Hypothyroidism? *Front Endocrinol (Lausanne).* 2019; 10:856. PMID: 31920970.
210. Epstein Y, Udassin R, Sack J. Serum 3,5,3'-triiodothyronine and 3,3',5'-triiodothyronine concentrations during acute heat load. *J Clin Endocrinol Metab.* 1979; 49:677-8. PMID: 489710.
211. Banovac K, Solter M, Sekso M *et al.* Relative increase of serum reverse T3 in patients with hypothyroidism. *Ann Endocrinol (Paris).* 1978; 39:387-91. PMID: 742837.
212. Banovac K, Bzik L, Sekso M, Petek M. Decreased ratio of serum T3:rT3 in patients with hyperthyroidism. *Endokrinologie.* 1978; 71:159-63. PMID: 668639.
213. Ruhla S, Arafat AM *et al.* T3/rT3-ratio is associated with insulin resistance independent of TSH. *Horm Metab Res.* 2011; 43:130-4. doi: 10.1055/s-0030-1267997. PMID: 21104580.
214. Biondi B, Wartofsky L. Combination treatment with T4 and T3: toward personalized replacement therapy in hypothyroidism? *J Clin Endocrinol Metab.* 2012; 97:2256-71. PMID: 22593590.
215. Seaborg E. *Endocrine news.* The Endocrine Society. 2017 Apr. <https://endocrinenews.endocrine.org/controversy-continues-combination-treatment-hypothyroidism/> Accessed 1.29.2020.
216. Dayan C, Panicker V. Management of hypothyroidism with combination thyroxine (T4) and triiodothyronine (T3) hormone replacement in clinical practice: a review of suggested guidance. *Thyroid Res.* 2018;11:1. PMID: 29375671.
217. Biondi B, Bartalena L *et al.* Recommendations for treatment of hypothyroidism with levothyroxine and levotriiodothyronine: a 2016 position statement of the Italian Society of Endocrinology and the Italian Thyroid Association. *J Endocrinol Invest.* 2016; 39:1465-1474. PMID: 27473077.

218. Tariq A, Wert Y, Cheriya P, Joshi R. Effects of Long-Term Combination LT4 and LT3 Therapy for Improving Hypothyroidism and Overall Quality of Life. *South Med J*. 2018; 111:363-369. PMID: 29863229.
219. Mori T, Inoue D *et al*. Effects of low dose L-triiodothyronine administration on mental, behavioural and thyroid states in elderly subjects. *Endocrinol Jpn*. 1988; 35:585-92. PMID: 3215145.
220. Davis PJ, Goglia F, Leonard JL. Nongenomic actions of thyroid hormone. *Nat Rev Endocrinol*. 2016; 12:111-21. PMID: 26668118.
221. Celi FS, Zemska M *et al*. Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine. *J Clin Endocrinol Metab*. 2011; 96:3466-74. PMID: 21865366.
222. Villafuerte, BC. U of Louisville Div. of Endocrinology Grand Rounds, May 2017.
223. Fish LH, Schwartz HL *et al*. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. *N Engl J Med*. 1987; 316:764-70. PMID: 3821822.
224. Gilman AG, Murad F. Thyroid and antithyroid drugs. Goodman LS, Gilman, A. *The pharmacological basis of therapeutics*. 5th Ed. New York. MacMillan Publishing Co. 1975. ISBN 0-02-344781-8.
225. Jonklaas J, Burman KD, Wang H, Latham KR. Single-dose T3 administration: kinetics and effects on biochemical and physiological parameters. *Ther Drug Monit*. 2015; 37:110-8. PMID: 24977379.
226. Saberi M, Utiger RD. Serum thyroid hormone and thyrotropin concentrations during thyroxine and triiodothyronine therapy. *J Clin Endocrinol Metab*. 1974; 39:923-7. PMID: 4422006.
227. den Brinker M, Joosten KF, Visser TJ *et al*. Euthyroid sick syndrome in meningococcal sepsis: the impact of peripheral thyroid hormone metabolism and binding proteins. *J Clin Endocrinol Metab*. 2005; 90:5613-20. PMID: 16076941.
228. Puig-Hernandez JF, Jimenez-Velez BD. High pressure liquid chromatography determination of the concentration and integrity of L-thyroxine in free T4 stock solution. *PR Health Sci J*. 2005; 24:151-6. PMID: 16116934.
229. Slater S. The discovery of thyroid replacement therapy. Part 3: A complete transformation. *J R Soc Med*. 2011; 104:100-6. PMID: 21357978.
230. Collin J. Letter from the Publisher. *Townsend Letter*. 2019 Dec; pg. 6.
231. Bhavnani BR, Stanczyk FZ. Pharmacology of conjugated equine estrogens: efficacy, safety and mechanism of action. *J Steroid Biochem Mol Biol*. 2014; 142:16-29. PMID: 24176763.
232. National Center for Biotechnology Information. PubChem Compound Summary for CID 5819, Levothyroxine. <https://pubchem.ncbi.nlm.nih.gov/compound/Levothyroxine>. Accessed Jan. 26, 2021.
233. Hernandez A. 3,5-diiodo-L-thyronine (t2) in dietary supplements: what are the physiological effects? *Endocrinology*. 2015; 156:5-7. PMID: 25526549.
234. Constantinou C, Margarity M, Valcana T. Region-specific effects of hypothyroidism on the relative expression of thyroid hormone receptors in adult rat brain. *Mol Cell Biochem*. 2005; 278:93-100. PMID: 16180094.

235. Li M, Boyages SC. Expression of beta2-thyroid hormone receptor in euthyroid and hypothyroid rat pituitary gland: an in situ hybridization and immunocytochemical study. *Brain Res.* 1997; 773:125-31. PMID: 9409713.
236. Mitsuhashi T, Nikodem VM. Regulation of expression of the alternative mRNAs of the rat alpha-thyroid hormone receptor gene. *J Biol Chem.* 1989; 264:8900-4. PMID: 2722806.
237. Heijckmann AC, Huijberts MS *et al.* Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma. *Eur J Endocrinol.* 2005; 153:23-9. PMID: 15994742.
238. Grais IM, Sowers JR. Thyroid and the heart. *Am J Med.* 2014; 127: 691-8. PMID: 24662620.
239. Thyroid – Drug Summary. PDR Prescribers’ Digital Reference. 2021. <https://www.pdr.net/drug-summary/armour-thyroid?druglabelid=2466> Accessed 1.26.2021.
240. Kirmızibekmez H, Yeşiltepe Mutlu RG. Atypical Presentation of Hashimoto's Disease in an Adolescent: Thyroid-Associated Ophthalmopathy. *J Clin Res Pediatr Endocrinol.* 2014; 6:262-5. PMID: 25541900.
241. Shahbaz A, Aziz K, Umair M, Sachmechi I. Prolonged Duration of Hashitoxicosis in a Patient with Hashimoto's Thyroiditis: A Case Report and Review of Literature. *Cureus.* 2018; 10:e2804. PMID: 30123726.
242. Takasu N, Matsushita M. Changes of TSH-Stimulation Blocking Antibody (TSBAb) and Thyroid Stimulating Antibody (TSAb) Over 10 Years in 34 TSBAb-Positive Patients with Hypothyroidism and in 98 TSAb-Positive Graves' Patients with Hyperthyroidism: Reevaluation of TSBAb and TSAb in TSH-Receptor-Antibody (TRAb)-Positive Patients. *J Thyroid Res.* 2012; 2012:182176. PMID: 22655217.
243. Schaffer A, Puthenpura V, Marshall I. Recurrent Thyrotoxicosis due to Both Graves' Disease and Hashimoto's Thyroiditis in the Same Three Patients. *Case Rep Endocrinol.* 2016; 2016:6210493. PMID: 27340576.
244. Ekpebegh C, Elmezughi K, Mtingi L. Graves' disease following hypothyroidism due to Hashimoto's thyroiditis in a black South African lady: a case report. *Pan Afr Med J.* 2019; 32:186. PMID: 31312298.
245. Pak S, Valencia D, Fershko A. Transformation of hashimoto thyroiditis to Graves' disease. *Res Rev Insights.* 2017 Oct 26; 1(3):1-2. doi: 10.15761/RRI.1000117.
246. Ross DS, Burch HB *et al.* 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. *Thyroid.* 2016; 26:1343-1421. Erratum in: *Thyroid.* 2017; 27:1462. PMID: 27521067.
247. Alexander EK, Marqusee E *et al.* Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. *N Engl J Med.* 2004; 351:241-9. PMID: 15254282.
248. Alexander EK, Pearce EN *et al.* 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. *Thyroid.* 2017; 27:315-389. Erratum in: *Thyroid.* 2017; 27:1212. PMID: 28056690.

249. Iijima S. Pitfalls in the assessment of gestational transient thyrotoxicosis. *Gynecol Endocrinol.* 2020; 36:662-667. PMID: 32301638.
250. Mazer NA. Interaction of estrogen therapy and thyroid hormone replacement in postmenopausal women. *Thyroid.* 2004; 14 Suppl 1:S27-34. PMID: 15142374.
251. Schindler AE. Thyroid function and postmenopause. *Gynecol Endocrinol.* 2003; 17:79-85. PMID: 12724022.
252. Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. *N Engl J Med.* 2001; 344:1743-9. PMID: 11396440.
253. Pearce SH, Brabant G *et al.* 2013 ETA Guideline: Management of Subclinical Hypothyroidism. *Eur Thyroid J.* 2013; 2:215-28. PMID: 24783053.
254. Surks MI, Ortiz E *et al.* Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. *JAMA.* 2004; 291:228-38. PMID: 14722150.
255. Col NF, Surks MI, Daniels GH. Subclinical thyroid disease: clinical applications. *JAMA.* 2004; 291:239-43. PMID: 14722151.
256. Bekkering GE, Agoritsas T *et al.* Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. *BMJ.* 2019; 365:l2006. doi: 10.1136/bmj.l2006. PMID: 31088853.
257. Cignini P, Cafà EV *et al.* Thyroid physiology and common diseases in pregnancy: review of literature. *J Prenat Med.* 2012; 6:64-71. PMID: 23272277.
258. Donnay S, Balsa JA *et al.* Burden of illness attributable to subclinical hypothyroidism in the Spanish population. *Rev Clin Esp (Barc).* 2013; 213:363-9. English, Spanish. PMID: 23773909.
259. Gencer B, Collet TH *et al.* Subclinical thyroid dysfunction and cardiovascular outcomes among prospective cohort studies. *Endocr Metab Immune Disord Drug Targets.* 2013; 13:4-12. PMID: 23369133.
260. Gerdes AM, Iervasi G. Thyroid replacement therapy and heart failure. *Circulation.* 2010; 122:385-93. PMID: 20660814.
261. Reid SM, Middleton P *et al.* Interventions for clinical and subclinical hypothyroidism pre-pregnancy and during pregnancy. *Cochrane Database Syst Rev.* 2013 May 31; (5):CD007752. PMID: 23728666.
262. Feller M, Snel M *et al.* Association of Thyroid Hormone Therapy With Quality of Life and Thyroid-Related Symptoms in Patients With Subclinical Hypothyroidism: A Systematic Review and Meta-analysis. *JAMA.* 2018; 320:1349-1359. PMID: 30285179.
263. Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ Jr. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. *N Engl J Med.* 1999; 340:424-9. PMID: 9971866.
264. Commonwealth of Kentucky Board of Medical Licensure, Case No. 1810. <http://www.state.ky.us/agencies/kbml/finalorders/36808.pdf> Accessed 2.3.2020.
265. Brent GA. Mechanisms of thyroid hormone action. *J Clin Invest.* 2012; 122:3035-43. PMID: 22945636.
266. Moran C, Agostini M *et al.* Contrasting Phenotypes in Resistance to Thyroid Hormone Alpha Correlate with Divergent Properties of Thyroid Hormone Receptor α 1 Mutant Proteins. *Thyroid.* 2017; 27:973-982. PMID: 28471274.

267. Dumitrescu AM, Refetoff S. Impaired Sensitivity to Thyroid Hormone: Defects of Transport, Metabolism and Action. *Endotext [Internet]*. 2015. PMID: 25905294.
268. Weiss RE, Dumitrescu A, Refetoff S. Approach to the patient with resistance to thyroid hormone and pregnancy. *J Clin Endocrinol Metab*. 2010; 95:3094-102. PMID: 20610605.
269. Ortiga-Carvalho TM, Sidhaye AR, Wondisford FE. Thyroid hormone receptors and resistance to thyroid hormone disorders. *Nat Rev Endocrinol*. 2014; 10:582-91. PMID: 25135573; PMCID: PMC4578869.
270. van Gucht ALM, Moran C *et al*. Resistance to Thyroid Hormone due to Heterozygous Mutations in Thyroid Hormone Receptor Alpha. *Curr Top Dev Biol*. 2017; 125:337-355. PMID: 28527577.
271. Groeneweg S, Visser WE, Visser TJ. Disorder of thyroid hormone transport into the tissues. *Best Pract Res Clin Endocrinol Metab*. 2017; 31:241-253. PMID: 28648511.
272. van der Deure WM, Appelhof BC *et al*. Polymorphisms in the brain-specific thyroid hormone transporter OATP1C1 are associated with fatigue and depression in hypothyroid patients. *Clin Endocrinol (Oxf)*. 2008; 69:804-11. PMID: 18410547.
273. Dumitrescu AM, Liao XH *et al*. Mutations in SECISBP2 result in abnormal thyroid hormone metabolism. *Nat Genet*. 2005; 37:1247-52. PMID: 16228000.
274. Di Cosmo C, McLellan N *et al*. Clinical and molecular characterization of a novel selenocysteine insertion sequence-binding protein 2 (SBP2) gene mutation (R128X). *J Clin Endocrinol Metab*. 2009; 94:4003-9. PMID: 19602558.
275. Starr, M . *Hypothyroidism Type 2: The Epidemic*. New Voice Publication. Revised 2013 edition. ISBN-13: 978-0975262405.
276. Ruiz-Núñez B, Tarasse R *et al*. Higher Prevalence of "Low T3 Syndrome" in Patients With Chronic Fatigue Syndrome: A Case-Control Study. *Front Endocrinol (Lausanne)*. 2018; 9:97. PMID: 29615976.
277. Boelen A, Platvoet-Ter Schiphorst MC, Wiersinga WM. Association between serum interleukin-6 and serum 3,5,3'-triiodothyronine in nonthyroidal illness. *J Clin Endocrinol Metab*. 1993; 77:1695-9. PMID: 8263160.
278. Panciera DL, Helfand SC, Soergel SA. Acute effects of continuous infusions of human recombinant interleukin-2 on serum thyroid hormone concentrations in dogs. *Res Vet Sci*. 1995; 58:96-7. PMID: 7709069.
279. Huang SA, Bianco AC. Reawakened interest in type III iodothyronine deiodinase in critical illness and injury. *Nat Clin Pract Endocrinol Metab*. 2008; 4:148-55. PMID: 18212764.
280. Wajner SM, Goemann IM *et al*. IL-6 promotes nonthyroidal illness syndrome by blocking thyroxine activation while promoting thyroid hormone inactivation in human cells. *J Clin Invest*. 2011; 121:1834-45. PMID: 21540553.
281. Poncin S, Lengelé B, Colin IM, Gérard AC. Differential interactions between Th1/Th2, Th1/Th3, and Th2/Th3 cytokines in the regulation of thyroperoxidase and dual oxidase expression, and of thyroglobulin secretion in thyrocytes in vitro. *Endocrinology*. 2008; 149:1534-42. PMID: 18187547.
282. Ott J, Promberger R *et al*. Hashimoto's thyroiditis affects symptom load and quality of life unrelated to hypothyroidism: a prospective case-control study in women

- undergoing thyroidectomy for benign goiter. *Thyroid*. 2011; 21:161-7. Erratum in: *Thyroid*. 2011; 21:467. PMID: 21186954.
283. Greenfield JR, Samaras K. Evaluation of pituitary function in the fatigued patient: a review of 59 cases. *Eur J Endocrinol*. 2006; 154(1):147-57. PMID: 16382004.
284. Harsan LA, Steibel J *et al*. Recovery from chronic demyelination by thyroid hormone therapy: myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging. *J Neurosci*. 2008; 28:14189-201. PMID: 19109501.
285. D'Intino G, Lorenzini L *et al*. Triiodothyronine administration ameliorates the demyelination/remyelination ratio in a non-human primate model of multiple sclerosis by correcting tissue hypothyroidism. *J Neuroendocrinol*. 2011; 23:778-90. PMID: 21707794.
286. Weiss RE, Stein MA, Refetoff S. Behavioral effects of liothyronine (L-T3) in children with attention deficit hyperactivity disorder in the presence and absence of resistance to thyroid hormone. *Thyroid*. 1997; 7:389-93. PMID: 9226208.
287. Parmentier T, Sienaert P. The use of triiodothyronine (T3) in the treatment of bipolar depression: A review of the literature. *J Affect Disord*. 2018 Mar 15;229:410-414. PMID: 29331701.
288. Touma KTB, Zoucha AM, Scarff JR. Liothyronine for Depression: A Review and Guidance for Safety Monitoring. *Innov Clin Neurosci*. 2017;14:24-29. PMID: 28584694.
289. Duntas LH, Maillis A. Hypothyroidism and depression: salient aspects of pathogenesis and management. *Minerva Endocrinol*. 2013; 38:365-77. PMID: 24285104.
290. Jackson IM. The thyroid axis and depression. *Thyroid*. 1998; 8:951-6. PMID: 9827665.
291. Gerdes AM, Iervasi G. Thyroid replacement therapy and heart failure. *Circulation*. 2010; 122:385-93. PMID: 20660814.
292. Marwali EM, Caesa P *et al*. Oral Triiodothyronine Supplementation Decreases Low Cardiac Output Syndrome After Pediatric Cardiac Surgery. *Pediatr Cardiol*. 2019; 40:1238-1246. PMID: 31309235.
293. Somppi TL. Non-Thyroidal Illness Syndrome in Patients Exposed to Indoor Air Dampness Microbiota Treated Successfully with Triiodothyronine. *Front Immunol*. 2017; 8:919. PMID: 28824644.
294. Levine DT. The definition of Optimal Metabolism and its association with large reductions in chronic diseases. *Trends Med*. 2018; 18:1-5. doi: 10.15761/TiM.1000122. <https://pdfs.semanticscholar.org/2eca/244add44f070f3e5d3ded6b08f5d15bd748c.pdf> Accessed 1.27.2021.
295. Friedman M, Miranda-Massari JR, Gonzalez MJ. Supraphysiological cyclic dosing of sustained release T3 in order to reset low basal body temperature. *P R Health Sci J*. 2006; 25:23-9. PMID: 16883675.